04/21
Headlines

NASDAQ:PTCT

FB Nasdaq FB Facebook

Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)

Colin Pettis02 mins

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. In April 2013, PTC Therapeutics, Inc. (NASDAQ:PTCT) initiated the confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) clinical trial evaluating ataluren as a potential treatment for patients with nonsense mutation…

Read More

Biotech Bearish Stocks: Reliv International (NASDAQ:RELV), Ocera Therapeutics (NASDAQ:OCRX), MediciNova (NASDAQ:MNOV), PTC Therapeutics (NASDAQ:PTCT)

Jayne Crisman02 mins

Registrant and three of its wholly-owned subsidiaries, Reliv, International, Inc (NASDAQ:RELV), Reliv World Corporation and SL Technology, Inc. entered into a Credit Agreement with BMO Harris Bank N.A. (the “Bank”) pursuant to which the Bank agreed to provide certain credit facilities to Registrant, including a Term Loan in the principal amount of $3,481,961 and a…

Read More

Biotech Decliners: Peregrine Pharmaceuticals (NASDAQ:PPHM), CytRx Corporation (NASDAQ:CYTR), PTC Therapeutics (NASDAQ:PTCT), Amicus Therapeutics (NASDAQ:FOLD)

Kristen Barton02 mins

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was -8.05% in last session and finished the day at $2.40. Traded volume was 14.14million shares in the last session and the average volume…

Read More

Sizzling Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT), Frontier Communications Corporation (NASDAQ:FTR), The Michaels Companies, Inc. (NASDAQ:MIK), Southwest Gas Corporation (NYSE:SWX), China Unicom (NYSE:CHU)

Kevin Long03 mins

PTC Therapeutics (NASDAQ:PTCT) EVP Neil Gregory Almstead sold 26,096 shares of PTC Therapeutics stock on the open market in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $60.26, for a total value of $1,572,544.96. PTC Therapeutics, Inc. (NASDAQ:PTCT) belongs to Healthcare sector. Its weekly performance is…

Read More

Active Watch List : Johnson & Johnson (NYSE:JNJ), Applied Materials, Inc. (NASDAQ:AMAT), PTC Therapeutics, Inc. (NASDAQ:PTCT), DIRECTV (NASDAQ:DTV), Phillips 66 Partners (NYSE:PSXP)

Chris Lewis02 mins

Johnson & Johnson (NYSE:JNJ) announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma’s portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently…

Read More

Healthcare Active Movers: Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), PTC Therapeutics, Inc. (NASDAQ:PTCT), Inovio Pharmaceuticals Inc (NYSEMKT:INO)

Jayne Crisman02 mins

US drugmaker Pfizer Inc (NYSE:PFE) on Monday abandoned its pursuit to buy AstraZeneca PLC, saying it does not plan to make an offer for the British drugmaker following the rejection of its final proposal last week. Pfizer Inc. (NYSE:PFE) stock performance was -0.57% in last session and finished the day at $29.49. Traded volume was…

Read More